Ascendis Pharma A/S (ASND) Stock Analysis & Investment Frameworks
Ascendis Pharma A/S (ASND) stock analysis on Invetso. Review Ascendis Pharma A/S’s key financial metrics, company overview and 10 institutional-grade investment frameworks including SWOT Analysis, Economic Moat, Porter’s Five Forces and the Invetso Quality Score.
Ascendis Pharma A/S Company Overview
- Exchange: NASDAQ Global Select
- Sector: Healthcare
- Industry: Biotechnology
- Country: DK
Ascendis Pharma A/S Key Financial Metrics
- Market Cap: $14.90B
- Revenue: $776.76M
- ROE: 190.44%
- ROIC: 5.80%
- Dividend Yield: N/A
About Ascendis Pharma A/S
Ascendis Pharma A/S is a biopharmaceutical enterprise dedicated to advancing therapeutic solutions for critical medical conditions that currently lack effective treatments. Its commercialized offering is SKYTROFA, a therapy prescribed for individuals suffering from growth hormone deficiency (GHD). The company boasts a robust development pipeline, featuring several TransCon-branded candidates. These include TransCon Growth Hormone (hGH), which is being progressed for pediatric GHD patients in Japan and for adults with GHD. Also under development are TransCon parathyroid hormone for adults with hypoparathyroidism, and TransCon CNP, aimed at treating pediatric achondroplasia. Further expanding its innovative portfolio, Ascendis is also developing a TransCon toll-like receptor (TLR) 7/8 agonist for intratumoral administration, alongside TransCon IL-2 ß/g, designed for systemic delivery. Founded in 2006, this enterprise maintains its corporate headquarters in Hellerup, Denmark.
Ascendis Pharma A/S Investment Frameworks
Invetso analyzes Ascendis Pharma A/S (ASND) across the following frameworks:
- Ascendis Pharma A/S 10Y Growth Potential
- Ascendis Pharma A/S Scenario Analysis
- Ascendis Pharma A/S Risks & Opportunities
- Ascendis Pharma A/S Economic Moat
- Ascendis Pharma A/S Business Model
- Ascendis Pharma A/S Management
- Ascendis Pharma A/S SWOT Analysis
- Ascendis Pharma A/S Porter's 5 Forces
- Ascendis Pharma A/S PESTLE Analysis
- Ascendis Pharma A/S ESG Analysis